Acrivon Therapeutics:FDA Grants Breakthrough Device Designation For ACR-368 OncoSignature Assay
The ACR-368-tailored OncoSignature assay is being used to identify patients most likely to respond to the company's lead drug candidate ACR-368 in an ongoing, registrational-intent, phase IIb trial in ...
How tracking blood sugar with continuous glucose monitoring may be helpful
Some experts claim that reducing fluctuations throughout the day can help protect against heart disease, even for people who ...